Kinderen, A. der

cancer screening treatment prostate cancer prostate therapy study smoking cessation percent disease cessation statin smoking population effect heart prevention aspirin age 60 group age 50 group 100 000 men table heart disease group interval level situation 10 years participant antihypertensive cost-effectiveness biopsy health netherland result statin therapy rotterdam death overdetected screen-detected cancers technology assessment strategy intervention 10- year risk psa screening analysis number trial 25 years smoker erspc overdetected cancers 10- overdetection 4- year interval estimate smoking cessation therapy blood pressure schroder fh nicotine blood european framingham 4- year intervals 30 percent screen european randomized study erspc trial bene fits psa test event model draisma surveillance technology screen-detected prostatectomy option assessment reduction